Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hematologic Non Malignancy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT05809284
What this trial is testing

Determining the Mechanisms of Loss of CAR T Cell Persistence

Who this might be right for
Acute Lymphoblastic Leukemia With Failed RemissionAcute Lymphoblastic Leukemia Not Having Achieved RemissionAcute Lymphoblastic Leukemia, Pediatric+2 more
University College, London 50
Not applicableLooking for participantsNCT06600568
What this trial is testing

Novel Therapeutic Approach for Human T-cell Malignancies

Who this might be right for
T-Cell Leukemia/Lymphoma, Adult
Istituto Oncologico Veneto IRCCS 120
Testing effectiveness (Phase 2)Ended earlyNCT02877082
What this trial is testing

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Who this might be right for
Acute LeukemiaChronic Lymphocytic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 Positive+9 more
Emory University 5
Testing effectiveness (Phase 2)Active Not RecruitingNCT02932280
What this trial is testing

Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

Who this might be right for
Solid TumorCentral Nervous System TumorLymphoma+1 more
Memorial Sloan Kettering Cancer Center 14
Testing effectiveness (Phase 2)UnknownNCT01802450
What this trial is testing

Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Who this might be right for
Chronic Myeloid Leukemia
PETHEMA Foundation 18
Very early researchStudy completedNCT02144623
What this trial is testing

Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
Lund University Hospital 4
Not applicableStudy completedNCT02075996
What this trial is testing

Non-interventional Study With Pomalidomide (Imnovid®)

Who this might be right for
Multiple Myeloma
iOMEDICO AG 151
Testing effectiveness (Phase 2)Ended earlyNCT00843310
What this trial is testing

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

Who this might be right for
Multiple Myeloma
NYU Langone Health 8
Testing effectiveness (Phase 2)Study completedNCT00989586
What this trial is testing

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
Beth Christian 35
Testing effectiveness (Phase 2)Study completedNCT00026182
What this trial is testing

Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular Lymphoma+4 more
National Cancer Institute (NCI) 99
Early research (Phase 1)Study completedNCT01019161
What this trial is testing

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

Who this might be right for
Acute Myeloid Leukaemia
AstraZeneca 5
Testing effectiveness (Phase 2)Ended earlyNCT01119794
What this trial is testing

Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab

Who this might be right for
Lymphoma, Non-Hodgkins
Brown University 10
Post-approval studies (Phase 4)WithdrawnNCT05183139
What this trial is testing

In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Takeda
Not applicableUnknownNCT04878822
What this trial is testing

Immunogenicity of Covid-19 Vaccination for Patients With Hematological Malignancies

Who this might be right for
ImmunogenicityHematological MalignanciesCovid-19+1 more
Ospedale di Circolo - Fondazione Macchi 300
Not applicableStudy completedNCT00080873
What this trial is testing

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

Who this might be right for
Kidney CancerLeukemiaLymphoma+3 more
Children's Oncology Group 195
Testing effectiveness (Phase 2)Ended earlyNCT01044745
What this trial is testing

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+108 more
University of Nebraska 20
Not applicableActive Not RecruitingNCT06125795
What this trial is testing

Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain

Who this might be right for
Chronic Lymphocytic Leukemia
AbbVie 146
Early research (Phase 1)Ended earlyNCT04219319
What this trial is testing

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma

Who this might be right for
CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)
The First Affiliated Hospital with Nanjing Medical University 4
Not applicableUnknownNCT05218603
What this trial is testing

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Who this might be right for
Multiple MyelomaNon-eligible for Autologous Stem Cell Transplantation (ASCT)
PETHEMA Foundation 100
Large-scale testing (Phase 3)UnknownNCT01615757
What this trial is testing

Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation

Who this might be right for
Acute Myeloid Leukemia
All India Institute of Medical Sciences 180
Next Page